NCT05886920View on ClinicalTrials.gov

Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 10, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions
Advanced Solid Tumors With MAPK Pathway Mutations
Interventions
DRUG

D3S-002

Oral

Trial Locations (10)

2148

D3 Bio Investigative Site, Blacktown

5042

D3 Bio Investigative Site, Bedford Park

6009

D3 Bio Investigative Site, Nedlands

10029

D3 Bio Investigative Site, New York

48202

D3 Bio Investigative Site, Detroit

100142

D3 Bio Investigative Site, Beijing

150081

D3 Bio Investigative Site, Harbin

201801

D3 Bio Investigative Site, Shanghai

310009

D3 Bio Investigative Site, Hangzhou

510080

D3 Bio Investigative Site, Guangzhou

All Listed Sponsors
lead

D3 Bio (Wuxi) Co., Ltd

INDUSTRY